immune thrombocytopenia itp children has vari cours accord durat distinguish newli diagnos 3 month persist 312 chronic 12 type sever studi have evalu prognost factor progress diseas similar work have yet perform greec aim identifi prognost marker three form diseas 57 greek children dure 13year period informat regard age gender preced infect bleed type durat symptom platelet diagnosi treatment diseas cours immunolog marker record 39 children had newli diagnos 4 persist 14 chronic diseas chronic itp children were more like age 10 year have gradual initi diseas platelet 10 10 9 impair immunolog marker compar newli diagnos persist group recent histori infect found main newli diagnos persist group none children exhibit sever spontan bleed conclus even though itp children usual has selflimit cours rare serious bleed complic chronic form diseas character differ predict paramet which can use clinic practic

Alexandros Makis

Athanasios Gkoutsias

Theodoros Palianopoulos

Eleni Pappa

Evangelia Papapetrou

Christina Tsaousi

Eleftheria Hatzimichael

Nikolaos Chaliasos

Prognostic Factors for Immune Thrombocytopenia Outcome in Greek Children: A Retrospective Single-Centered Analysis

era precis medicin impact person dose busulfan clear undertook retrospect analysi 78 patient myeloid malign who receiv fludarabin busulfan flubu4 without measur pharmacokinet those who receiv busulfan cyclophosphamid buci fiftyf patient receiv flubu4 whom 21 had measur 23 patient receiv buci total donor cell chimer show percentag patient maintain 100 donor chimer day 100 667 382 739 flubu4 flubu4 buci respect 001 patient who had decreas donor chimer day 100 were 238 529 261 flubu4 flubu4 buci respect 04 group had fewer patient less than 95 donor chimer day 30 which statist signific 5 flubu4 31 flubu4 21 buci 18 surviv distribut were statist signific 11 thus person drug dose can impact donor chimer myeloid malign this need examin larger retrospect multicent studi prospect clinic trial

Shatha Farhan

Michael Bazydlo

Klodiana Neme

Nancy Mikulandric

Edward Peres

Nalini Janakiraman

Chimerism in Myeloid Malignancies following Stem Cell Transplantation Using FluBu4 with and without Busulfan Pharmacokinetics versus BuCy

improve therapi urgent need patient diffus larg cell lymphoma dlbcl success use immun checkpoint inhibitor chimer antigen receptor cell technolog has fuell demand valid cancer epitop immunogen cancer testi antigen ctas widespread express mani tumour high restrict normal tissu distribut repres attract immunotherapeut target may improv treatment option dlbcl other malign sperm protein 17 sp17 cta report immunogen ovarian cancer myeloma patient express dlbcl the aim present studi investig sp17 epitop present via presenc cytotox cell ctl cd4 thelper respons dlbcl patient signific interferon ctl respons detect peripher blood mononuclear cell 1331 dlbcl patient follow shortterm cell stimul two novel hla 0201 peptid one previous report hla 0101restrict ninem sp17 peptid signific respons were detect hla 0201negat dlbcl patient four healthi subject novel immunogen 20mer cd4 sp17 peptid detect 817 dlbcl patient this first report ctl cd4 respons sp17 dlbcl support sp17 potenti immunotherapeut target dlbcl

Kamel Ait-Tahar

Amanda P. Anderson

Martin Barnardo

Graham P. Collins

Chris S. R. Hatton

Alison H. Banham

Karen Pulford

Sp17 Protein Expression and Major Histocompatibility Class I and II Epitope Presentation in Diffuse Large B Cell Lymphoma Patients

the current studi investig function state erythrocyt indic oxygenbind capac hemoglobin blood sampl from healthi donor from patient coronari arteri diseas myocardi infarct befor after treatment has been establish cardiovascular diseas erythrocyt morpholog hemoglobin oxygentransport disord observ standard therapi doe result restor structur properti erythrocyt the author believ necessari futur therapeut treatment includ prepar other than cardiovascular agent enhanc capac hemoglobin transport oxygen tissu

Victor V. Revin

Antonina A. Ushakova

Natalia V. Gromova

Larisa A. Balykova

Elvira S. Revina

Vera V. Stolyarova

Tatiana A. Stolbova

Ilya N. Solomadin

Alexander Yu. Tychkov

Nadezhda V. Revina

Oksana G. Imarova

Study of Erythrocyte Indices, Erythrocyte Morphometric Indicators, and Oxygen-Binding Properties of Hemoglobin Hematoporphyrin Patients with Cardiovascular Diseases

relaps refractori acut myeloid leukemia rraml associ poor prognosi longterm diseasefre surviv requir allogen hematopoiet cell transplant allohct limit data exist regard optim regimen obtain remiss prior allohct singl agent highdos cytarabin 1012 dose administ everi 12 hour has been previous use induct therapi sixdos highdos cytarabin hidac6 common use consolid regimen has never been evalu induct therapi present retrospect review 26 consecut patient rraml receiv singl agent cytarabin 3 2 intraven everi 12 hour day 1 3 5 total six dose hidac6 median followup surviv patient 104 month rang 161122 month complet remiss obtain 62 54 8 cri patient the median relapsefre surviv rfs 223 month rang 07112 month eventfre surviv efs 47 month rang 05112 month overal surviv 96 month rang 1112 month thirtyf percent patient were abl subsequ proceed allohct treatmentrel toxic includ neutropen fever 38 infect 35 neurotox 8 skin toxic 8 this first studi demonstr hidac6 activ treatment option younger patient rraml which can effect serv bridg allohct without signific toxic

Brandi Anders

Lauren Veltri

Abraham S. Kanate

Alexandra Shillingburg

Nilay Shah

Michael Craig

Aaron Cumpston

Outcomes of Six-Dose High-Dose Cytarabine as a Salvage Regimen for Patients with Relapsed/Refractory Acute Myeloid Leukemia

introduct the realiz red cell exchang rce africa face lack blood transfus safeti equip evalu it efficaci safeti sever complic sickl cell diseas patient method manual partial rce perform among sickl cell patient who had sever complic efficaci evalu clinic evolut blood count electrophoresi hemoglobin safeti evalu advers effect infect alloimmun result perform 166 partial rce among 44 patient includ 41 homozyg 2 heterozyg composit 1 0thalassemia the mean age 279 year the sex ratio 158 the regress symptom complet 100 persist vasoocclus crisi acut chest syndrom 567 intermitt priapism 30 stroke partial 100 leg ulcer null acut priapism the mean variat hemoglobin hematocrit rate after one procedur were respect 14 44 that hemoglobin after 2 consecut rce 60 neither alloimmun nor viral seroconvers observ conclus this work show feasibl manual partial rce lowresourc set it efficaci safeti dure complic scd outsid acut priapism

B. F. Faye

D. Sow

M. Seck

N. Dieng

S. A. Toure

M. Gadji

A. B. Senghor

Y. B. Gueye

D. Sy

A. Sall

T. N. Dieye

A. O. Toure

S. Diop

Efficacy and Safety of Manual Partial Red Cell Exchange in the Management of Severe Complications of Sickle Cell Disease in a Developing Country

multipl myeloma heterogen hematolog malign involv prolifer plasma cell deriv differ genet event contribut develop progress prognosi diseas despit improv treatment strategi over last decad diseas remain incur all effort current focus understand prognost marker diseas hope incorpor new therapeut modal convert diseas curabl one present comprehens review summar current standard prognost marker use along novel techniqu still develop highlight implic current clinic practic

Amr Hanbali

Mona Hassanein

Walid Rasheed

Mahmoud Aljurf

Fahad Alsharif

The Evolution of Prognostic Factors in Multiple Myeloma

About this journal

Advances in Hematology publishes original research articles, review articles, and clinical studies in all areas of hematology.

Journal profile

Meet the editorial board

Advances in Hematology maintains an Editorial Board of practicing researchers from around the world, to ensure manuscripts are handled by editors who are experts in the field of study.

Editor spotlight

Submit to Special Issue

We currently have a number of Special Issues open for submission. Special Issues highlight emerging areas of research within a field, or provide a venue for a deeper investigation into an existing research area.

Advances in Hematology